The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature
Open accessAbstract
This paper follows the immunotherapy symposium held during the European Association of Nuclear Medicine (EANM) 2017 Annual Congress. The biological basis of the immune checkpoint inhibitors and the drugs most frequently used for the treatment of solid tumours are reviewed. The issues of pseudoprogression (frequency, timeline), hyperprogression and immune-related side effects are discussed, as well as their implications for patient management. A review of the recent literature on the use of FDG PET for assessment of immunotherapy is presented, and recommendations are provided for assessing tumour response and reporting immune-related side effects with FDG PET based on published data and experts' experience. Representative clinical cases are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S., Chaput, N., Eggermont, A., Marabelle, A., Soria, J.-C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1741 · Cited by 1,190
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2925 · Cited by 1,003
Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L., & Hansen, A. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx286 · Cited by 939
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review
Friedman, C. F., Proverbs-Singh, T. A., & Postow, M. A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1051 · Cited by 802
Hodi, F. S., Hwu, W.-J., Kefford, R., Weber, J. S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 734
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606
Saâda-Bouzid, E., Defaucheux, C., Karabajakian, A., Coloma, V. P., Servois, V., Paoletti, X., Even, C., Fayette, J., Guigay, J., Loirat, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx178 · Cited by 596
Self-citationQuantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis
Chicklore, S., Goh, V., Siddique, M., Roy, A., Marsden, P. K., & Cook, G. J. R. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2247-0 · Cited by 488
Aide, N., Lasnon, C., Veit-Haibach, P., Sera, T., Sattler, B., & Boellaard, R. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3740-2 · Cited by 344
Self-citationGeukes Foppen, M. H., Rozeman, E. A., van Wilpe, S., Postma, C., Snaebjornsson, P., van Thienen, J. V., van Leerdam, M. E., van den Heuvel, M., Blank, C. U., van Dieren, J., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000278 · Cited by 274
Cho, S. Y., Lipson, E. J., Im, H.-J., Rowe, S. P., Gonzalez, E. M., Blackford, A., Chirindel, A., Pardoll, D. M., Topalian, S. L., & Wahl, R. L. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.188839 · Cited by 251
Mazzaschi, G., Madeddu, D., Falco, A., Bocchialini, G., Goldoni, M., Sogni, F., Armani, G., Lagrasta, C. A., Lorusso, B., Mangiaracina, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2156 · Cited by 248
Anwar, H., Sachpekidis, C., Winkler, J., Kopp-Schneider, A., Haberkorn, U., Hassel, J. C., & Dimitrakopoulou-Strauss, A. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3870-6 · Cited by 197
Kaira, K., Higuchi, T., Naruse, I., Arisaka, Y., Tokue, A., Altan, B., Suda, S., Mogi, A., Shimizu, K., Sunaga, N., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3806-1 · Cited by 195
Fujii, T., Colen, R. R., Bilen, M. A., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., Alshawa, A., Hong, D. S., Tsimberidou, A., Janku, F., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0534-0 · Cited by 179
Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers
Vanpouille-Box, C., Formenti, S. C., & Demaria, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0037 · Cited by 171
Merelli, B., Massi, D., Cattaneo, L., & Mandalà, M. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.002 · Cited by 170
Spigel, D. R., Chaft, J. E., Gettinger, S., Chao, B. H., Dirix, L., Schmid, P., Chow, L. Q. M., Hicks, R. J., Leon, L., Fredrickson, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.004 · Cited by 159
Self-citationLopci, E., Toschi, L., Grizzi, F., Rahal, D., Olivari, L., Castino, G. F., Marchetti, S., Cortese, N., Qehajaj, D., Pistillo, D., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3425-2 · Cited by 154
Self-citationSachpekidis, C., Larribère, L., Pan, L., Haberkorn, U., Dimitrakopoulou‐Strauss, A., & Hassel, J. C. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2944-y · Cited by 152
Horne, Z. D., Jack, R., Gray, Z. T., Siegfried, J. M., Wilson, D. O., Yousem, S. A., Nason, K. S., Landreneau, R. J., Luketich, J. D., & Schuchert, M. J. (2011) · Journal of Surgical Research · doi:10.1016/j.jss.2011.03.068 · Cited by 133
Sachpekidis, C., Anwar, H., Winkler, J. K., Kopp‐Schneider, A., Larribère, L., Haberkorn, U., Hassel, J. C., & Dimitrakopoulou‐Strauss, A. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3972-9 · Cited by 108
Takada, K., Toyokawa, G., Okamoto, T., Baba, S., Kozuma, Y., Matsubara, T., Haratake, N., Akamine, T., Takamori, S., Katsura, M., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1215 · Cited by 100
Kong, B. Y., Menzies, A. M., Saunders, C. A. B., Liniker, E., Ramanujam, S., Guminski, A. D., Kefford, R. F., Long, G. V., & Carlino, M. S. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12503 · Cited by 97
Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
Cousin, S., & Italiano, A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2569 · Cited by 83
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician
Lheureux, S., Denoyelle, C., Ohashi, P. S., Bono, J. S. D., & Mottaghy, F. M. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3695-3 · Cited by 81
Self-citationRossi, S., Toschi, L., Castello, A., Grizzi, F., Mansi, L., & Lopci, E. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3802-5 · Cited by 67
Self-citationImmune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT
Wachsmann, J. W., Ganti, R., & Peng, F. (2017) · Academic Radiology · doi:10.1016/j.acra.2016.08.005 · Cited by 63
Lasnon, C., Majdoub, M., Lavigne, B., Dô, P., Madelaine, J., Visvikis, D., Hatt, M., & Aide, N. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3441-2 · Cited by 53
Self-citationTsai, K. K., Pampaloni, M. H., Hope, C. B., Algazi, A. P., Ljung, B., Pincus, L. B., & DAUD, A. I. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0162-9 · Cited by 44
Lasnon, C., Enilorac, B., Popotte, H., & Aide, N. (2017) · EJNMMI Research · doi:10.1186/s13550-017-0279-y · Cited by 36
Self-citationFDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
Higuchi, M., Owada, Y., Inoue, T., Watanabe, Y., Yamaura, T., Fukuhara, M., Hasegawa, T., & Suzuki, H. Y. (2016) · World Journal of Surgical Oncology · doi:10.1186/s12957-016-0998-y · Cited by 28
Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?
Sharon, E. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2926 · Cited by 18
Cited by
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Metadata
- Authors
- Aide, N., Hicks, R. J., Le Tourneau, C., Lheureux, S., Fanti, S., & Lopci, E.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2018-10-05
- Volume
- 46
- Issue
- 1
- Pages
- 238-250
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2895608724
- Cited by
- 263
- References
- 43
- FWCI
- 18.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.